Skip to main content
. 2016 Aug 23;49(2):484–493. doi: 10.4143/crt.2016.246

Fig. 2.

Fig. 2.

The 10-year locoregional recurrence-free survival rate between patients aged < 40 years (blue line) and ≥ 40 years (red line) for luminal subtypes (A), nonluminal subtypes (B), luminal A (C), human epidermal growth factor receptor type 2 (HER2)–enriched (D), luminal B (E), and triple negative subtypes (F).